Bloomberg reports the obesity drug market is expected to reach as much as $130 billion in annual sales by 2030.

The findings were in line with those of a large retrospective cohort study that showed that patients treated with GLP-1 ...

AbbVie Inc. ( NYSE: ABBV) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET Scott T. Reents - Executive Vice President and Chief Financial Officer Jeffrey R. Stewart - Executive ...

While some drugs have fallen off, more have been added: AbbVie recently jumped into the obesity craze by licensing an ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.

In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...

Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...

"Significant stockholders" now control a vast majority of the struggling company's shares and have left the door open for a ...